1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer

1,3,5-Triazine scaffold has garnered considerable interest due to its wide-ranging pharmacological properties, particularly in the field of Cancer research. Breast Cancer is the most commonly diagnosed Cancer among women. Approximately one in eight women will receive a diagnosis of invasive breast Cancer during their lifetime. The five-year survival rate for invasive breast Cancer is less than 30 %, indicating a need to develop a more effective therapeutic agent targeting breast Cancer. This review discusses bioactive 1,3,5-triazines targeting breast Cancer cells by the inhibition of different Enzymes, which include PI3K, mTOR, EGFR, VEGFR, FAK, CDK, DHFR, DNA Topoisomerase, ubiquitin-conjugating enzyme, Carbonic Anhydrase, and matrix metalloproteinase. The Anticancer agent search in some drug discovery programs is based on compound screening for antiproliferative activity. Often, multiple targets contribute to the Anticancer effect of 1,3,5-triazines and this approach allows identification of active molecules prior to identification of their targets.

1,3,5-triazine; Anticancer agent; Breast cancer; Triazines.